生物气溶胶研究进展  

Research progress of bioaerosols

作　　者：陈雪琴 李姗 张明顺[2,3] 吉宁飞 黄茂 CHEN Xueqin;LI Shan;ZHANG Mingshun;JI Ningfei;HUANG Mao(Department of Respiratory and Critical Care Medicine,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029;Key Laboratory of Antibody Techniques of National Health Commission,Nanjing 211166,China;Department of Immunology,Nanjing Medical University,Nanjing 211166,China)

机构地区：[1]南京医科大学第一附属医院呼吸与危重症医学科,江苏南京210029 [2]南京医科大学国家卫生健康委员会抗体技术重点实验室,江苏南京211166 [3]南京医科大学免疫学系,江苏南京211166

出　　处：《南京医科大学学报（自然科学版）》2020年第6期783-787,792,共6页Journal of Nanjing Medical University(Natural Sciences)

基　　金：2020年度江苏省重点研发计划(BE2020616)。

摘　　要：自2019年12月以来,新型冠状病毒肺炎(coronavirus disease 2019,COVID-19)已引起全球大流行。我国最新COVID-19诊疗方案指出,在相对封闭的环境中长时间暴露于高浓度气溶胶情况下存在经气溶胶传播的可能。气溶胶是固体或液体颗粒在气体中的悬浮物,由于其空气动力学直径小,易在下呼吸道沉积,与飞沫相比更易引起肺炎等严重疾病。本文对生物气溶胶作文献复习并阐述其对COVID-19防护带来的启示。The coronavirus disease 2019(COVID-19)has now caused a global pandemic since it appeared in December 2019.According to the latest Diagnosis and Treatment Protocol for COVID-19 in China,the possibility of aerosol transmission exists under the condition of prolonged exposure to high concentrations of aerosol in a relatively closed environment.Aerosols are suspensions in air of solid or liquid particles.Due to their small aerodynamic diameter,bioaerosols are prone to deposit in the lower respiratory tract and are more likely to cause severe diseases such as pneumonia than droplets.This review will brush up on the literature on bioaerosols and expound its implications for the protection of COVID-19.

关 键 词：生物气溶胶 新型冠状病毒肺炎 

分 类 号：R512.99[医药卫生—内科学]